EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study

Anita Gąsiorowska iD, Marek Romanowski, Ewa Walecka-Kapica, Aleksandra Kaczka, Cezary Chojnacki iD, Milena Padysz, Marta Siedlecka, Julia Banasik, Aleksandra Sobolewska-Włodarczyk, Maria Wiśniewska-Jarosińska, Joanna B Bierła iD, Nize Otaru und 2 weitere

Journal of Clinical Medicine · 24.12.2024 · 14 (1) · 6

DOI: 10.3390/jcm14010006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.12.2024. Verfasst von Anita Gąsiorowska und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DSM-Firmenich (Kaiseraugst, Switzerland).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess the efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics (Lactocaseibacillus rhamnosus DSM 26357, Lactobacillus acidophilus DSM 32418, Bifidobacterium longum DSM 32946, Bifidobacterium bifidum DSM 32403, and Bifidobacterium lactis DSM 32269), and short-chain fructooligosaccharides (scFOSs) in IBS patients.

Methods

This was a randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS. The primary outcome of the 12-week intervention was the improvement in IBS symptoms and quality of life (QOL), assessed with the use of IBS-Adequate Relief (IBS-AR), IBS-Global Improvement Scale (IBS-GIS), IBS-Symptom Severity Score (IBS-SSS), and IBS-QOL. Secondary outcomes were the number and type of stools (assessed via the Bristol Stool Form scale), patient-recorded symptoms, anthropometric parameters, and levels of selected inflammatory cytokines.

Results

As early as at 4 weeks, there was a higher percentage of patients in the biotic group reporting adequate relief of symptoms (based on IBS-AR) than in the placebo group (64.7% vs. 42.0%, respectively, p = 0.023). At 12 weeks, fewer patients in the biotic group reported a ‘worsening of symptoms’ (based on IBS-GIS) than in the placebo group (5.9% vs. 16.0% respectively, p = 0.015). There were no significant differences between groups in IBS-QOL or IBS-SSS or any of the secondary outcome measures except the patient-recorded ‘urgency to defecate’ (p = 0.015) at week 12, which was significantly lower in the biotic group. The intervention was safe and well tolerated.

Conclusions

A biotic mixture consisting of microencapsulated butyrate, probiotics, and small amounts of scFOSs is safe and effective in improving gastrointestinal symptoms in patients with IBS.

Schlagwörter

Stichwörter der Autor:innen

irritable bowel syndromemicroencapsulated sodium butyrateprebioticsprobioticssynbiotics

Autor:innen und Institutionen

  • Gastroenterology Department, Medical University of Lodz, Pomorska 251, 92-213 Łódź, Poland.
  • Department of Microbiology and Clinical Immunology, The Children's Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.
  • Health, Nutrition & Care, DSM-Firmenich, 4303 Kaiseraugst, Switzerland.
  • Department of Pathomorphology, The Children's Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland.
  • Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich, 8091 Zürich, Switzerland.

ORCID-Profile: Anita Gąsiorowska, Cezary Chojnacki, Joanna B Bierła, Bożena Cukrowska

Förderung

  • DSM-Firmenich (Kaiseraugst, Switzerland)

Zitieren

APA

Gąsiorowska, A., Romanowski, M., Walecka-Kapica, E., Kaczka, A., Chojnacki, C., Padysz, M., Siedlecka, M., Banasik, J., Sobolewska-Włodarczyk, A., Wiśniewska-Jarosińska, M., Bierła, J. B., Otaru, N., Cukrowska, B., & Steinert, R. E. (2024). Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Medicine, 14(1), 6. https://doi.org/10.3390/jcm14010006

Vancouver

Gąsiorowska A, Romanowski M, Walecka-Kapica E, Kaczka A, Chojnacki C, Padysz M, et al. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Medicine. 2024;14(1):6. doi:10.3390/jcm14010006

BibTeX
@article{Gsiorowska2024,
  author = {Gąsiorowska, Anita and Romanowski, Marek and Walecka-Kapica, Ewa and Kaczka, Aleksandra and Chojnacki, Cezary and Padysz, Milena and Siedlecka, Marta and Banasik, Julia and Sobolewska-Włodarczyk, Aleksandra and Wiśniewska-Jarosińska, Maria and Bierła, Joanna B and Otaru, Nize and Cukrowska, Bożena and Steinert, Robert E},
  title = {Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome—A Randomized, Double-Blind, Placebo-Controlled Study},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {14},
  number = {1},
  pages = {6},
  doi = {10.3390/jcm14010006}
}
Kostenlos starten →